JD
Therapeutic Areas
Alumis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Envudeucitinib (ESK-001) | Moderate-to-Severe Plaque Psoriasis | Phase 3 |
| Envudeucitinib | Moderate-to-Severe Systemic Lupus Erythematosus | Phase 2 |
| A-005 | Undisclosed Immune-Mediated Disease | Discovery/Preclinical |
Leadership Team at Alumis
MB
Martin Babler
President, Chief Executive Officer and Chairman of the Board
MB
Mark Bradley
Chief Development Officer
KB
Kolbot By
SVP, Head of Technical Operations
JD
Jörn Drappa
Chief Medical Officer
DM
David M Goldstein
Chief Scientific Officer
GH
Grace Halteh
SVP, Head of Quality and Regulatory
RH
Roy Hardiman
Chief Business and Strategy Officer
CL
Claire Langrish
SVP, Head of Immunology and Translational Science
SP
Sanam Pangali
Chief Legal Officer and Corporate Secretary
JS
John Schroer
Chief Financial Officer